Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years~* Subjects who obtain a minimum sum score, considering Seasonal Allergic Rhinitis (SAR) related symptoms (mean value), as defined by the protocol~Exclusion Criteria:~* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety~* Have used forbidden concomitant medications as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): Placebo was administered orally on Days 1 and 2.
- Montelukast (MLKT) (Type: EXPERIMENTAL): 10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
- Levocetirizine (LCTZ) (Type: EXPERIMENTAL): 5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).